Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fasting State

An Open Label, Randomized, Single Dose, Cross-over ,Two-group Study to Evaluate the Pharmacokinetics and Safety of DA-1229_01 2.5/500mg in Healthy Subjects at Fasting State

This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01(2.5/500 mg) at fasting state.

Inclusion Criteria:

• Healthy Volunteers
• BMI between 18 and 30 kg/m2
• Body weight : Male≥50kg, Female≥45kg

Exclusion Criteria:

• Allergy or Drug hypersensitivity
• Clinically significant Medical History